November 2, 2017 (Boston) – International law firm Proskauer advised Frazier Healthcare Partners on the first and final closing of Frazier Life Sciences IX, L.P. The fund reached its hard cap and closed on nearly $419 million in capital commitments. Frazier Life Sciences IX, L.P. is the second dedicated life sciences fund the investment firm has raised.

Frazier Healthcare Partners is a leading provider of growth and venture capital to healthcare companies. It has raised nearly $3.4 billion in total capital and has invested in more than 170 companies, with investment types ranging from company creation and venture capital to buyouts of profitable lower-middle market companies. Frazier’s Life Sciences Team invests in therapeutics and related areas that are addressing unmet medical needs through innovation.

Our team was led by partner Robin Painter and included associates Stephen Meli, Ryan Carpenter and Matt Geduldig (Private Funds); partner Jamiel Poindexter and associate Kyle Litfin (Tax).

Proskauer offers a full suite of services for the investment management industry, with a market-leading global team dedicated solely to advising asset managers, investment funds and their advisers, financial institutions and institutional investors across the asset class. The cross border team of over 130 lawyers is based in the U.S., UK, Asia and Latin America and includes specialists in tax, ERISA, regulation, financial services, employment, insurance, fund finance, litigation and risk management who understand the unique technical and commercial issues relevant to investment managers.